LatestOpinion: Why Life Insurers' Rejection of Active Surveillance for Prostate Cancer Misses the Mark
Health

Hospital Cabral y Báez Presents Clinical Research at International Neurology and Neurosurgery Congress

Diario Salud Redacción
Hospital Cabral y Báez Presents Clinical Research at International Neurology and Neurosurgery Congress
Summary

The Neurology Department at Hospital Regional Universitario José María Cabral y Báez showcased three clinical research papers at the 34th International Congress of Neurology and Neurosurgery, organized by the Dominican Society of Neurology and Neurosurgery. The presentations featured case studies of neurological interest, contributing to the advancement of medical knowledge in the field. This conference brought together leading specialists, medical residents, and healthcare professionals to discuss innovations in neurological and neurosurgical care. Such presentations strengthen the hospital's role as a center of clinical excellence and research in the Dominican Republic.

Originally published on

DiarioSalud.do

By Diario Salud Redacción

Read full article(opens in new tab)

Fetched: October 7, 2026 at 10:01 AM

Related News

More news you might be interested in

View all
Opinion: Why Life Insurers' Rejection of Active Surveillance for Prostate Cancer Misses the Mark
Health
Cancer

Opinion: Why Life Insurers' Rejection of Active Surveillance for Prostate Cancer Misses the Mark

A patient advocates against insurance companies classifying prostate cancer under active surveillance as 'untreated cancer,' arguing that close monitoring by oncologists represents legitimate medical management. Active surveillance is an established clinical approach for low-risk prostate cancer that avoids unnecessary aggressive treatments while maintaining vigilant oversight. Insurance companies' mischaracterization of this evidence-based strategy may unfairly penalize patients and limit access to appropriate care. This issue highlights the growing tension between medical standards of care and insurance industry practices in cancer management.

3 hours ago
STAT News
Democrats Engage MAHA Voters with Food and Environmental Health Initiatives
Health

Democrats Engage MAHA Voters with Food and Environmental Health Initiatives

Key Democratic leaders are meeting with Make America Healthy Again (MAHA) activists and unveiling comprehensive food and environmental health plans ahead of the midterm elections. These initiatives focus on addressing public health concerns related to nutrition and environmental factors that impact community wellness. The outreach represents a strategic effort to appeal to voters prioritizing preventive health measures and sustainable food systems. Environmental health policies can significantly reduce disease burden and improve population health outcomes across diverse demographics.

3 hours ago
STAT News
STAT+: Duchenne Muscular Dystrophy Patients Face Unequal Access to Promising Therapy
Health

STAT+: Duchenne Muscular Dystrophy Patients Face Unequal Access to Promising Therapy

Exon-skipping drugs offer new hope for Duchenne muscular dystrophy patients, but access remains severely limited to only a fortunate few. These innovative therapies represent a critical test of the FDA's commitment to advancing rare disease treatments. The stark disparity in access raises important questions about equity and affordability in precision medicine. Patients and families are forced to navigate complex eligibility criteria and astronomical costs, highlighting the challenges in delivering breakthrough therapies to all who need them. This situation underscores the ongoing tension between innovation and accessibility in orphan drug development.

3 hours ago
STAT News
Caribou Biosciences Shuts Down After Failing to Fund CAR-T Lymphoma Trial
Health
Cancer

Caribou Biosciences Shuts Down After Failing to Fund CAR-T Lymphoma Trial

Caribou Biosciences, a biotech company co-founded by Nobel Prize winner Jennifer Doudna, is shutting down after failing to secure funding for a late-stage clinical trial of its off-the-shelf CAR-T cell therapy designed to treat lymphoma. CAR-T therapy is an innovative immunotherapy approach that genetically engineers patients' immune cells to recognize and attack cancer cells. The company's closure represents a setback in developing more accessible CAR-T treatments, as off-the-shelf formulations could potentially benefit more patients compared to personalized approaches. This outcome highlights the significant financial challenges biotech companies face in advancing cancer treatments through clinical development stages.

3 hours ago
STAT News